FLXN | Flexion Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2014-02-12

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	257
Country	USA
Website	FLXN

Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

FLXN's peers: PETS, MSON, AIRS, AFMD, YMAB, SIBN, OCGN, SEER, CPSI, JANX

*Chart delayed

Analyzing fundamentals for FLXN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see FLXN Fundamentals page.

Watching at FLXN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on FLXN Technicals page.